Clinical innovation in Europe takes shape within a dense regulatory environment that is moving toward more transparency, stronger patient involvement and, increasingly, multilingual accessibility. For pharmaceutical companies, this evolution turns language from a simple operational detail into a strategic component of clinical development and market access.
In this context, medical translation is no longer just about “making documents available” in several languages. It has become a key lever to support innovation, support compliance and build trust with patients, healthcare professionals and authorities. This article explores how high‑quality translation can genuinely support clinical innovation in a harmonised European regulatory framework, and what this means in practice for sponsors and their language partners.
A harmonised regulatory framework, a multilingual reality
With the EU Clinical Trials Regulation (CTR) 536⁄2014, Europe has taken a major step toward harmonising the way clinical trials are authorised, conducted and supervised. The CTR introduces a single submission portal (CTIS), clearer timelines and more structured transparency requirements. It also reinforces the obligation to provide information that is understandable for laypersons, in particular through lay summaries of clinical trial results.
At the same time, the multilingual reality of the European Union has not disappeared. Member states continue to set their own language requirements for documents submitted to ethics committees and competent authorities, as well as for patient‑facing materials such as informed consent forms, information leaflets, questionnaires and follow‑up documents. This means sponsors must operate within a harmonised framework while managing a complex mosaic of linguistic expectations and local practices.
For global and European pharmaceutical companies, this dual movement has very concrete consequences. It calls for :
- A central, coherent content and terminology strategy that can be applied across countries and languages.
- A robust process to adapt, translate and validate documents in line with both EU‑level rules and national requirements.
- A clear understanding that translation is not a late add‑on, but an integrated part of regulatory planning and risk management.
In other words, harmonisation does not simplify the linguistic dimension. It makes it more visible, more structured and more closely linked to compliance.
Lay summaries and patient‑facing content : clarity as a regulatory requirement
One of the most emblematic changes brought by the CTR is the requirement to produce lay summaries of clinical trial results. These documents are designed for non‑specialists and must present, in accessible terms, why the trial was conducted, how it was designed, what results were obtained and what these results mean. They are published at EU level, but need to be understandable to patients and citizens in different countries and linguistic contexts.
Here, translation plays a central role. A lay summary that is clear in its original language but becomes ambiguous, overly technical or culturally disconnected once translated will not fulfil its purpose. Beyond compliance, this also undermines the trust that patients and the general public place in clinical research.
The same applies to informed consent documents, information sheets and any material designed for participants. The goal is not simply to “simplify” the language, but to ensure that people genuinely understand :
- The objectives and methodology of the trial.
- The potential risks, constraints and benefits.
- Their rights as participants, including the right to withdraw.
This requires translators who are able to work at the intersection of medical concepts, regulatory expectations and plain‑language writing. It also requires close collaboration between sponsors, clinical teams, regulatory affairs and language partners to align on terminology, tone and cultural references.
Digital and structured information : new challenges for consistency
In parallel with the CTR, Europe is accelerating the digitalisation of medicinal product information. Electronic Product Information (ePI) projects, supported by the European Medicines Agency (EMA) and national agencies, aim to make information such as the Summary of Product Characteristics (SmPC), package leaflets and labelling available in electronic, structured and easily updatable formats.
This transformation offers clear benefits : faster updates for safety signals, better integration with digital health tools, and more direct access to reliable information for healthcare professionals and patients. But it also brings new challenges from a linguistic and translation perspective.
Structured content makes inconsistencies easier to detect. A discrepancy between the SmPC and the package leaflet, or between two language versions, becomes more immediately apparent when information is stored, compared and displayed in a structured way. Similarly, when digital information is reused across different channels (web portals, apps, hospital systems), translation errors or approximations can propagate more widely and more quickly.
To support this evolution, pharmaceutical companies need translation processes that are :
- Anchored in a robust terminology framework, aligned with regulatory and scientific references.
- Designed to work with modular, reusable content segments rather than static documents only.
- Capable of ensuring consistency across languages, across formats and over time, even as regulations and internal templates evolve.
Here again, the question is not whether to translate, but how to integrate translation in a way that supports innovation rather than slowing it down or introducing additional risk.
Quality, risk and responsibility : why translation is a compliance topic
In clinical development, every piece of content has a function : inform, convince, document, protect, demonstrate, or sometimes all of the above. Poorly translated content can compromise each of these functions.
A term that is too vague, a sentence that can be interpreted in two different ways, an inconsistency between the protocol, the informed consent form and the lay summary – each of these “linguistic details” can create real issues : misunderstandings by investigators or participants, delays in approvals, requests for clarification from authorities, or even patient safety risks if instructions are misinterpreted.
In practice, this means that translation quality is a matter of :
- Regulatory compliance : alignment with EU‑level texts and national expectations, including the correct use of mandatory formulations where applicable.
- Risk management : preventing confusion or misinterpretation, especially in patient‑facing documents and safety‑critical information.
- Ethics : ensuring that participants are treated with respect and given information they can understand and use to make informed decisions.
For sponsors, the responsibility does not end with outsourcing translation to a provider. They remain fully accountable for the content they submit and communicate. This responsibility extends to the way translation workflows are organised, documented and controlled : selection of translators, review cycles, use of glossaries and style guides, traceability of changes, and alignment between languages.
The role of a specialist language partner
In this complex landscape, working with a specialist language partner can make a tangible difference. For ClaviS, the starting point is clear : translation is first and foremost a human act, supported by technology when appropriate, but never reduced to a purely automated process.
Supporting clinical innovation in a harmonised regulatory framework means :
- Relying on native, expert medical translators who understand both the scientific content and the regulatory environment in which it will be used.
- Building dedicated teams around therapeutic areas or client portfolios, so that terminology, tone and expectations are mastered over time.
- Putting in place rigorous review and quality‑control procedures, including medical review where required, to secure the accuracy and coherence of content.
- Maintaining strict confidentiality and data security practices, particularly when sensitive clinical data or unpublished results are involved.
- Integrating technology – including translation memories, terminology databases and, where appropriate, AI‑based tools – in a reasoned way, without compromising meaning or nuance.
This approach is grounded in a long‑term partnership mindset. The goal is not only to translate the documents for the next submission or the next trial, but to support the overall multilingual strategy of the client, in line with its brand, its values and its obligations.
Human expertise and AI : a balanced approach
The rise of artificial intelligence, including generative AI, is also transforming the landscape of medical communication and translation. These tools can accelerate certain tasks, help explore alternative formulations or support internal teams in drafting early versions of documents. They are valuable when used with clear frameworks and human oversight.
However, in highly regulated contexts such as clinical trials and pharmaceutical product information, AI must remain a tool, not a decision‑maker. The risk of subtle errors, hallucinated content or inappropriate simplifications is incompatible with the level of responsibility involved. A nuanced sentence, a carefully chosen term or a culturally sensitive example cannot be delegated blindly to an algorithm.
For ClaviS, integrating AI means :
- Evaluating on a case‑by‑case basis where technology can genuinely support efficiency without diluting quality.
- Ensuring that any AI‑assisted output is systematically reviewed, corrected and validated by experienced human translators.
- Protecting client data by avoiding uncontrolled use of open tools and implementing secure, compliant technological solutions when needed.
This balanced approach makes it possible to benefit from innovation while remaining fully aligned with the ethical and regulatory expectations of the pharmaceutical field.
From words to relationships : what is at stake for brands
Beyond regulations and processes, there is another dimension that matters for sponsors : how their communication is perceived by patients, healthcare professionals, authorities and partners. Clinical innovation is not only a scientific or regulatory achievement ; it is also a matter of trust.
Consistent, clear, culturally adapted multilingual communication contributes directly to this trust. It shows respect for participants, demonstrates seriousness toward authorities and reflects a coherent brand identity across markets. Conversely, clumsy translations, inconsistent terminology or texts that “sound like a machine” can weaken that trust and damage the perceived quality of the company’s work, even when the science and the regulatory strategy are robust.
This is where the broader mission of a language partner like ClaviS comes into play : preserving the voice of each client across languages, ensuring that the same care applied to study design and regulatory strategy is reflected in the words chosen to communicate it.
Accompanying clinical innovation over the long term
The European regulatory landscape will continue to evolve. Transparency requirements may expand, digital channels will multiply, and patient expectations regarding information quality will grow. In this dynamic environment, seeing translation as a one‑off service is no longer sufficient.
Supporting clinical innovation in a harmonised European framework means building a long‑term, structured relationship between sponsors and their language partners. It means :
- Anticipating language implications early in clinical and regulatory planning.
- Aligning internal stakeholders (clinical operations, regulatory affairs, medical, communication) around a shared multilingual strategy.
- Investing in consistent terminology, style and processes that can be applied across studies and markets.
Above all, it means recognising that, in a multilingual Europe, innovation is not only about what you discover in the lab or demonstrate in a trial. It is also about how clearly, faithfully and respectfully you make that innovation understood – in every language where it matters.
